Management


Pioneers in an innovation-driven market

The experienced management uses all ist specialized expertise for a successful biosimilar development.

Dr. Carsten Brockmeyer

CEO

Dr. Nicolas Combé

CFO

Dr. Stefan Glombitza

COO

Dr. Stefan Glombitza

CEO

Dr. Nicolas Combé

CFO

Nicola Mikulcik

CBO

Dr. Andreas Seidl

CSO

Dr. Stefan Glombitza


Stefan Glombitza has more than twenty years of extensive experience in the pharmaceutical industry and has distinctive expertise in the generics sector. After studying pharmacy at the University of Regensburg and subsequently gaining his PhD, he began his professional career in 1995 as Medical Affairs Manager at Hexal AG. After two years as head of the medical department, he established a project management system in the development area and ultimately was appointed to the management board of Hexal Pharmaforschung as head of project management.

With the takeover by Novartis in 2005, Dr. Glombitza’s remit expanded to cover leadership of global project and portfolio management within Sandoz’s generics division. After several years in this role he switched to the German business organization to set up the new cross-functional unit Pharmaceutical Affairs. He managed this business unit for four years until 2013, when he became head of the global development center at the austrian Sandoz facilities in Kundl and Schaftenau. Since October 2016 Stefan Glombitza has been Chief Operating Officer (COO) at Formycon, with operational responsibility for the company’s development activities.

Dr. Nicolas Combé


Dr. Nicolas Combé, PhD, received his degree in business administration from Philipps University in Marburg, Germany, as well as a degree in European Management Science from the University of Kent, UK. He went on to receive his doctoral degree in economics in Marburg, with a dissertation on development and innovation theory.

In 2006, Nicolas Combé was among the founders of NanoRepro AG, serving as the company’s CFO from 2007 to 2009 and successfully leading multiple financing rounds as well as the company’s listing on the Frankfurt Stock Exchange. In 2008 he co-founded the company that was later to become Formycon AG. He has served as its CFO since 2010 and played a key role in the company’s restructuring and strategic reorientation through the acquisition of the development unit at the company’s present headquarters in Martinsried. As CFO and executive board member of Formycon, Nicolas Combé is responsible for the areas of finance/controlling, human resources, legal, PR/IR and facilities management.

Nicola Mikulcik


  • Held leading management positions at Hexal and Sandoz International
  • More than 20 years of extensive experience in pharmaceutical industry
  • Outstanding expertise in Product Development, Business Development and Commercial Affairs
  • Former Managing Director of Bioeq GmbH

Dr. Andreas Seidl


Dr. Andreas Seidl has more than 20 years of experience in the pharmaceutical industry and biotechnology. He studied chemistry with a focus on biochemistry followed by a PhD in the field of protein analytics at the University of Konstanz. He started his professional career outside the university in 2002 at Hexal Biotech GmbH, a subsidiary of Hexal AG, where he pioneered strategies for the development and approval of biosimilars. Among other things, he was able to make decisive contributions to the development of the first complex biosimilar, Epoetin alfa Hexal/Binocrit.

From 2002 to 2010, as Head of Analytics and Quality Control, he was responsible for analytical pharmaceutical development and quality control of the first biosimilars. After the integration of Hexal AG into the Novartis Group, he managed several analytical development departments at the Oberhaching site from 2010 to 2015 and was appointed site manager there. In this role, he was also responsible for a GLP/GCLP-certified testing laboratory for preclinical and clinical analytics. From 2015 to 2019, he was assigned responsibility for several bioanalytical groups in Germany, Austria and Switzerland within the Novartis global development organization, supporting the successful development and approval of a total of eight biosimilars but also innovative biologics during this time.

From 2019 to mid-2022, Dr. Andreas Seidl served as COO on the board of Leukocare AG, an innovative biotech company in Martinsried near Munich, Germany, providing formulation and finished product development for all types of biologics (proteins, antibodies, viral vectors, vaccines, biofunctionalized medical devices) for the pharmaceutical and biotech industry. As CSO of Formycon AG since July 2022, Dr. Andreas Seidl is in charge of the scientific strategy and is responsible for Scientific Affairs as well as preclinical and clinical development on the Executive Board.